EUROFINS SCIENT (ERFSF)
(Delayed Data from OTC)
$64.41 USD
+2.49 (4.02%)
Updated Apr 17, 2024 11:55 AM ET
1-Strong Buy of 5 1
B Value C Growth B Momentum B VGM
Balance Sheet
Fiscal Year End for EUROFINS SCIENT falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 519 | 610 | 1,042 | 333 |
Receivables | NA | 1,253 | 1,335 | 1,159 | 1,204 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 153 | 182 | 179 | 89 |
Other Current Assets | NA | 513 | 616 | 496 | 171 |
Total Current Assets | NA | 2,437 | 2,744 | 2,877 | 1,797 |
Net Property & Equipment | NA | 2,284 | 2,165 | 1,799 | 1,785 |
Investments & Advances | NA | 88 | 97 | 65 | 61 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 80 | 108 | 88 | 49 |
Intangibles | NA | 5,735 | 5,928 | 4,968 | 5,070 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 10,624 | 11,041 | 9,796 | 8,762 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 682 | 743 | 619 | 459 |
Current Portion Long-Term Debt | NA | 225 | 300 | 271 | 509 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 37 | 102 | 96 | 23 |
Other Current Liabilities | NA | 923 | 1,051 | 951 | 780 |
Total Current Liabilities | NA | 1,867 | 2,195 | 1,938 | 1,771 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 141 | 146 | 132 | 139 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 3,279 | 2,958 | 3,332 | 3,457 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 226 | 208 | 149 | 148 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 5,513 | 5,507 | 5,551 | 5,516 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 2 | 2 | 2 | 2 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | 2,458 | 2,324 | 1,497 | 805 |
Other Equity | NA | 2,666 | 3,212 | 2,746 | 2,439 |
Treasury Stock | NA | 15 | 4 | 0 | 0 |
Total Shareholder's Equity | NA | 5,111 | 5,534 | 4,245 | 3,246 |
Total Liabilities & Shareholder's Equity | NA | 10,624 | 11,041 | 9,796 | 8,762 |
Total Common Equity | 0 | 5,111 | 5,534 | 4,245 | 3,246 |
Shares Outstanding | 192.40 | 192.40 | 192.20 | 178.00 | 178.00 |
Book Value Per Share | 0.00 | 26.56 | 28.79 | 23.85 | 18.24 |
Fiscal Year End for EUROFINS SCIENT falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 755 | -99,999 |
Receivables | NA | NA | NA | 1,284 | NA |
Notes Receivable | NA | NA | NA | NA | NA |
Inventories | NA | NA | NA | 164 | NA |
Other Current Assets | NA | NA | NA | 616 | NA |
Total Current Assets | NA | NA | NA | 2,819 | NA |
Net Property & Equipment | NA | NA | NA | 2,407 | NA |
Investments & Advances | NA | NA | NA | 88 | NA |
Other Non-Current Assets | NA | NA | NA | NA | NA |
Deferred Charges | NA | NA | NA | 79 | NA |
Intangibles | NA | NA | NA | 5,859 | NA |
Deposits & Other Assets | NA | NA | NA | NA | NA |
Total Assets | NA | NA | NA | 11,251 | NA |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | NA |
Accounts Payable | NA | NA | NA | 616 | NA |
Current Portion Long-Term Debt | NA | NA | NA | 159 | NA |
Current Portion Capital Leases | NA | NA | NA | NA | NA |
Accrued Expenses | NA | NA | NA | NA | NA |
Income Taxes Payable | NA | NA | NA | 26 | NA |
Other Current Liabilities | NA | NA | NA | 1,164 | NA |
Total Current Liabilities | NA | NA | NA | 1,965 | NA |
Mortgages | NA | NA | NA | NA | NA |
Deferred Taxes/Income | NA | NA | NA | 140 | NA |
Convertible Debt | NA | NA | NA | NA | NA |
Long-Term Debt | NA | NA | NA | 3,412 | NA |
Non-Current Capital Leases | NA | NA | NA | NA | NA |
Other Non-Current Liabilities | NA | NA | 208 | NA | |
Minority Interest (Liabilities) | NA | NA | NA | NA | NA |
Total Liabilities | NA | NA | NA | 5,725 | NA |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | NA |
Common Stock (Par) | NA | NA | NA | 2 | NA |
Capital Surplus | NA | NA | NA | NA | NA |
Retained Earnings | NA | NA | NA | 2,465 | NA |
Other Equity | NA | NA | NA | 3,111 | NA |
Treasury Stock | NA | NA | NA | 52 | NA |
Total Shareholder's Equity | NA | NA | NA | 5,526 | NA |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 11,251 | NA |
Total Common Equity | 0 | 0 | 0 | 105,525 | 0 |
Shares Outstanding | 192.40 | 192.40 | 192.40 | 192.40 | 192.40 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 548.47 | 0.00 |